Inflammation and pancreatic cancer: molecular and functional interactions between S100A8, S100A9, NT-S100A8 and TGFβ1. 2014

Daniela Basso, and Dania Bozzato, and Andrea Padoan, and Stefania Moz, and Carlo-Federico Zambon, and Paola Fogar, and Eliana Greco, and Michele Scorzeto, and Francesca Simonato, and Filippo Navaglia, and Matteo Fassan, and Michela Pelloso, and Sirio Dupont, and Sergio Pedrazzoli, and Ambrogio Fassina, and Mario Plebani
Department of Laboratory Medicine, University-Hospital of Padova, Via Giustiniani 2, 35128 Padova, Italy. daniela.basso@sanita.padova.it.

BACKGROUND In order to gain further insight on the crosstalk between pancreatic cancer (PDAC) and stromal cells, we investigated interactions occurring between TGFβ1 and the inflammatory proteins S100A8, S100A9 and NT-S100A8, a PDAC-associated S100A8 derived peptide, in cell signaling, intracellular calcium (Cai2+) and epithelial to mesenchymal transition (EMT). NF-κB, Akt and mTOR pathways, Cai2+ and EMT were studied in well (Capan1 and BxPC3) and poorly differentiated (Panc1 and MiaPaCa2) cell lines. RESULTS NT-S100A8, one of the low molecular weight N-terminal peptides from S100A8 to be released by PDAC-derived proteases, shared many effects on NF-κB, Akt and mTOR signaling with S100A8, but mainly with TGFβ1. The chief effects of S100A8, S100A9 and NT-S100A8 were to inhibit NF-κB and stimulate mTOR; the molecules inhibited Akt in Smad4-expressing, while stimulated Akt in Smad4 negative cells. By restoring Smad4 expression in BxPC3 and silencing it in MiaPaCa2, S100A8 and NT-S100A8 were shown to inhibit NF-κB and Akt in the presence of an intact TGFβ1 canonical signaling pathway. TGFβ1 counteracted S100A8, S100A9 and NT-S100A8 effects in Smad4 expressing, not in Smad4 negative cells, while it synergized with NT-S100A8 in altering Cai2+ and stimulating PDAC cell growth. The effects of TGFβ1 on both EMT (increased Twist and decreased N-Cadherin expression) and Cai2+ were antagonized by S100A9, which formed heterodimers with TGFβ1 (MALDI-TOF/MS and co-immuno-precipitation). CONCLUSIONS The effects of S100A8 and S100A9 on PDAC cell signaling appear to be cell-type and context dependent. NT-S100A8 mimics the effects of TGFβ1 on cell signaling, and the formation of complexes between TGFβ1 with S100A9 appears to be the molecular mechanism underlying the reciprocal antagonism of these molecules on cell signaling, Cai2+ and EMT.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016212 Transforming Growth Factor beta A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins. Bone-Derived Transforming Growth Factor,Platelet Transforming Growth Factor,TGF-beta,Milk Growth Factor,TGFbeta,Bone Derived Transforming Growth Factor,Factor, Milk Growth,Growth Factor, Milk
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D051057 Proto-Oncogene Proteins c-akt Protein-serine-threonine kinases that contain PLECKSTRIN HOMOLOGY DOMAINS and are activated by PHOSPHORYLATION in response to GROWTH FACTORS or INSULIN. They play a major role in cell metabolism, growth, and survival as a core component of SIGNAL TRANSDUCTION. Three isoforms have been described in mammalian cells. akt Proto-Oncogene Protein,c-akt Protein,AKT1 Protein Kinase,AKT2 Protein Kinase,AKT3 Protein Kinase,Akt-alpha Protein,Akt-beta Protein,Akt-gamma Protein,Protein Kinase B,Protein Kinase B alpha,Protein Kinase B beta,Protein Kinase B gamma,Protein-Serine-Threonine Kinase (Rac),Proto-Oncogene Protein Akt,Proto-Oncogene Protein RAC,Proto-Oncogene Proteins c-akt1,Proto-Oncogene Proteins c-akt2,Proto-Oncogene Proteins c-akt3,RAC-PK Protein,Rac Protein Kinase,Rac-PK alpha Protein,Rac-PK beta Protein,Related to A and C-Protein,c-akt Proto-Oncogene Protein,Akt alpha Protein,Akt beta Protein,Akt gamma Protein,Akt, Proto-Oncogene Protein,Protein, akt Proto-Oncogene,Protein, c-akt Proto-Oncogene,Proteins c-akt1, Proto-Oncogene,Proteins c-akt2, Proto-Oncogene,Proteins c-akt3, Proto-Oncogene,Proto Oncogene Protein Akt,Proto Oncogene Protein RAC,Proto Oncogene Proteins c akt,Proto Oncogene Proteins c akt1,Proto Oncogene Proteins c akt2,Proto Oncogene Proteins c akt3,Proto-Oncogene Protein, akt,Proto-Oncogene Protein, c-akt,RAC PK Protein,RAC, Proto-Oncogene Protein,Rac PK alpha Protein,Rac PK beta Protein,Related to A and C Protein,akt Proto Oncogene Protein,alpha Protein, Rac-PK,c akt Proto Oncogene Protein,c-akt, Proto-Oncogene Proteins,c-akt1, Proto-Oncogene Proteins,c-akt2, Proto-Oncogene Proteins,c-akt3, Proto-Oncogene Proteins
D051901 Smad4 Protein A signal transducing adaptor protein and tumor suppressor protein. It forms a complex with activated RECEPTOR-REGULATED SMAD PROTEINS. The complex then translocates to the CELL NUCLEUS and regulates GENETIC TRANSCRIPTION of target GENES. Common Smad,MADH4 Protein,Smad, Common

Related Publications

Daniela Basso, and Dania Bozzato, and Andrea Padoan, and Stefania Moz, and Carlo-Federico Zambon, and Paola Fogar, and Eliana Greco, and Michele Scorzeto, and Francesca Simonato, and Filippo Navaglia, and Matteo Fassan, and Michela Pelloso, and Sirio Dupont, and Sergio Pedrazzoli, and Ambrogio Fassina, and Mario Plebani
November 2006, Biochemical pharmacology,
Daniela Basso, and Dania Bozzato, and Andrea Padoan, and Stefania Moz, and Carlo-Federico Zambon, and Paola Fogar, and Eliana Greco, and Michele Scorzeto, and Francesca Simonato, and Filippo Navaglia, and Matteo Fassan, and Michela Pelloso, and Sirio Dupont, and Sergio Pedrazzoli, and Ambrogio Fassina, and Mario Plebani
October 2018, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
Daniela Basso, and Dania Bozzato, and Andrea Padoan, and Stefania Moz, and Carlo-Federico Zambon, and Paola Fogar, and Eliana Greco, and Michele Scorzeto, and Francesca Simonato, and Filippo Navaglia, and Matteo Fassan, and Michela Pelloso, and Sirio Dupont, and Sergio Pedrazzoli, and Ambrogio Fassina, and Mario Plebani
May 2013, Free radical biology & medicine,
Daniela Basso, and Dania Bozzato, and Andrea Padoan, and Stefania Moz, and Carlo-Federico Zambon, and Paola Fogar, and Eliana Greco, and Michele Scorzeto, and Francesca Simonato, and Filippo Navaglia, and Matteo Fassan, and Michela Pelloso, and Sirio Dupont, and Sergio Pedrazzoli, and Ambrogio Fassina, and Mario Plebani
May 2023, Biochimica et biophysica acta. Reviews on cancer,
Daniela Basso, and Dania Bozzato, and Andrea Padoan, and Stefania Moz, and Carlo-Federico Zambon, and Paola Fogar, and Eliana Greco, and Michele Scorzeto, and Francesca Simonato, and Filippo Navaglia, and Matteo Fassan, and Michela Pelloso, and Sirio Dupont, and Sergio Pedrazzoli, and Ambrogio Fassina, and Mario Plebani
February 2019, Scientific reports,
Daniela Basso, and Dania Bozzato, and Andrea Padoan, and Stefania Moz, and Carlo-Federico Zambon, and Paola Fogar, and Eliana Greco, and Michele Scorzeto, and Francesca Simonato, and Filippo Navaglia, and Matteo Fassan, and Michela Pelloso, and Sirio Dupont, and Sergio Pedrazzoli, and Ambrogio Fassina, and Mario Plebani
June 2023, BMC cancer,
Daniela Basso, and Dania Bozzato, and Andrea Padoan, and Stefania Moz, and Carlo-Federico Zambon, and Paola Fogar, and Eliana Greco, and Michele Scorzeto, and Francesca Simonato, and Filippo Navaglia, and Matteo Fassan, and Michela Pelloso, and Sirio Dupont, and Sergio Pedrazzoli, and Ambrogio Fassina, and Mario Plebani
December 2018, BMC cancer,
Daniela Basso, and Dania Bozzato, and Andrea Padoan, and Stefania Moz, and Carlo-Federico Zambon, and Paola Fogar, and Eliana Greco, and Michele Scorzeto, and Francesca Simonato, and Filippo Navaglia, and Matteo Fassan, and Michela Pelloso, and Sirio Dupont, and Sergio Pedrazzoli, and Ambrogio Fassina, and Mario Plebani
March 2024, Immunology,
Daniela Basso, and Dania Bozzato, and Andrea Padoan, and Stefania Moz, and Carlo-Federico Zambon, and Paola Fogar, and Eliana Greco, and Michele Scorzeto, and Francesca Simonato, and Filippo Navaglia, and Matteo Fassan, and Michela Pelloso, and Sirio Dupont, and Sergio Pedrazzoli, and Ambrogio Fassina, and Mario Plebani
May 2018, The Journal of clinical investigation,
Daniela Basso, and Dania Bozzato, and Andrea Padoan, and Stefania Moz, and Carlo-Federico Zambon, and Paola Fogar, and Eliana Greco, and Michele Scorzeto, and Francesca Simonato, and Filippo Navaglia, and Matteo Fassan, and Michela Pelloso, and Sirio Dupont, and Sergio Pedrazzoli, and Ambrogio Fassina, and Mario Plebani
October 2011, Antioxidants & redox signaling,
Copied contents to your clipboard!